Diabetes Technology in the Spotlight: 10 EASD Highlights was posted by Diabetotech.com, 21 October 2023.
Listed below are the top ten highlights from this year’s EASD Congress from Dr. Inge Boxelaer of Diabetotech, referencing the comprehensive reporting from Kelly Close of Close Concerns. Read down through the post for all of the items.
- #1 Real-world Data from MiniMed 780G of >100,000 Users
- #2 Simplera Sensor Achieves CE label
- #3 Head-to-head Study of Automated Insulin Delivery (AID) Systems
- #4 Tandem Examines Algorithm to Simplify Tandem Control-IQ Settings
- #5 Real-world Data from Nearly 70,000 Omnipod 5 Users
- #6 AiDAPT Study Confirms Safety and Effectiveness of AID Systems for Pregnant Women with Type 1 Diabetes
- #7 CamAPS HX: Full AID System for Adults with Type 1 Diabetes
- #8 INREDA Shows Impressive Results with Bihormonal AID System
- #9 More Asian Glucose Sensors
- #10 The Future of Glycaemic Control: Time in Tight Range?
Dario smart glucose meter now compatible with iPhone by Kays Khalil for MedicalDevice-Network.com, 2 November 2023. The latest models of Apple iPhones now have access to Dario Health’s smart glucose meter.
US-based digital health company Dario has announced the launch of a new smart blood sugar meter for Apple iPhone 15 users. Following the iPhone’s recent switch to a type-C USB port, iPhone 15 users can now get direct connectivity for live blood sugar readings through Dario’s health management tools.
Now compatible with both Android and Apple users, the pocket-sized device includes a glucose meter, disposable test strip cartridge, and a lancing device. It can automatically log results and promises to keep the user constantly connected to their care provider.
Talking with Tandem Diabetes about the Mobi & more with Stacey Simms of Diabetes-Connections.com, 31 October 2023.
Tandem’s tiny Mobi pump is FDA-approved and set for a limited rollout in the next few weeks. We’ve got a deep dive into its features. Mobi is phone-controlled, but it has a button that delivers insulin and more..
Stacey Simms interviewed Ben Mar, Tandem’s Director of Product Marketing, about all of those features, answering a bunch of your questions about Mobi and about what else is coming up for Tandem.
Sibionics wins CE mark for GS1 CGM System by Jenna Philpott for MedicalDevice-Network.com, 2 November 2023. The device, which received marketing approval in China in 2021, offers users 14 days of continuous glucose monitoring without the need for frequent calibration.
Chinese company Sibionics has obtained a CE Mark for its GS1 continuous glucose monitoring system (CGM), a wearable device that uses an under-the-skin sensor to measure glucose levels in real-time, transmitting the information to a linked handset or mobile phone.
The GS1 CGM offers users 14 days of continuous glucose monitoring without the need for frequent calibration. It allows users to transmit glucose data to monitoring devices or mobile apps and generate professional reports.
An additional feature of the system supports data sharing with friends and family and integrates the ProView remote access platform for healthcare providers to monitor and intervene.
Read more: Sibionics wins CE mark for GS1 CGM System
Join a Type 1 Diabetes Trial Testing Insulin-Producing Cells posted by diaTribe.org, 26 October 2023.
This study is investigating whether Vertex’s VX-264, an encapsulated stem cell therapy, can safely restore insulin-producing islet cell function to people with type 1 diabetes without the need for lifelong immunosuppressive medication.
- Clinical Trials Identifier: NCT05791201
- Trial Name: A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
- Diabetes Type: Adults with type 1 diabetes
- Trial Sponsor: Vertex Pharmaceuticals
This study is investigating whether VX-264, an encapsulated human stem cell therapy developed by Vertex, can safely restore insulin production in people with type 1 diabetes – without requiring lifelong immunosuppressive medication.
Vertex’s VX-264 therapy keeps beta cells in an enclosed device, physically protecting them from the body’s immune cells while still allowing nutrients to reach the beta cells, a strategy known as encapsulation. There is hope that, when encapsulated, the insulin-producing stem cell therapy will be safer, more convenient, and eliminate the lifelong need for immunosuppressive medication.
This phase 1 and phase 2 study, which is currently enrolling and will run through 2026, plans to enroll 17 participants. Researchers will evaluate the safety of VX-264 in participants over a period of two years. They will also measure changes in average total daily insulin dose and A1C, and observe if participants are able to reach insulin independence.
You may be eligible to participate if you are between the ages of 18-65 years old, were diagnosed with type 1 diabetes at least five years ago, have been using a continuous glucose monitor (CGM) for at least four weeks, and have not had prior cell therapy or organ transplants. The trial is currently recruiting in Miami, Chicago, Boston, and Pittsburgh in the U.S., Edmonton and Toronto in Canada, and Leiden in the Netherlands. See more details on inclusion and exclusion criteria here.
To learn more about this study, contact Vertex’s medical information team at email@example.com or call 617-341-6777.
FOOD FOR THOUGHT
The amount of insulin on the left is 2 units and is needed when a person with Type 1 Diabetes, eats about 10 carbohydrates. The amount of insulin on the right is 10 units and is enough to be fatal in a matter of a few hours. This is the difference between life and death. There’s not much margin for error.
Dosing decisions are required every time a T1D eats.
Sit on that for a minute . . .
Every meal, every single day, every holiday, every party, every vacation.